EP Patent

EP3768245A4 — Melanocortin receptor-specific peptide formulations and methods for gastrointestinal tract-specific delivery

Assigned to Palatin Technologies Inc · Expires 2023-10-18 · 3y expired

What this patent protects

Patent listed against risedronate-sodium.

Drugs covered by this patent

risedronate-sodium (RISEDRONATE SODIUM)

Patent Metadata

Patent number: EP3768245A4
Jurisdiction: EP
Classification: —
Expires: 2023-10-18
Drug substance claim: No
Drug product claim: No
Assignee: Palatin Technologies Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.